Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
81.68
+0.53 (+0.65%)
4:02:26 PM EDT: $81.69 +0.01 (+0.01%)
Products

Merck & Ridgeback Announce Submission Of EUA Application To U.S. FDA For Molnupiravir, For Treatment Of Mild-To-Moderate Covid-19 In At Risk Adults

Published: 10/11/2021 12:34 GMT
Merck & Co Inc (MRK) - Merck & Ridgeback Announce Submission of Eua Application to U.S. FDA for Molnupiravir, for Treatment of Mild-to-moderate Covid-19 in at Risk Adults.
Merck - Eua Submission for Molnupiravir Based on Positive Results From Planned Interim Analysis From Phase 3 Move-out Clinical Trial.
Further Company Coverage: Mrkn ((reuters.
Briefs@thomsonreuters.
Com;)).